Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10307
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJackson, Ben
dc.contributor.authorMendelsohn, Frederick AOen
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-15T23:43:13Z
dc.date.available2015-05-15T23:43:13Z
dc.date.issued1991-05-16en
dc.identifier.citationJournal of Cardiovascular Pharmacology; 18 Suppl 7(): S4-8en
dc.identifier.govdoc1725200en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10307en
dc.description.abstractAngiotensin-converting enzyme (ACE) is a widely distributed dipeptidyl carboxydipeptidase. Using computer analysis of the binding of radiolabeled ACE inhibitors, we have mapped the distribution of ACE in normal animals and in models of disease, and have studied the tissue effects of ACE inhibitors. In the myocardium, ACE is located in vascular and valvular structures as well as in the atria and ventricles. Its concentration is increased in myocardial hypertrophy in the infarct model of heart failure. Chronic ACE-inhibitor therapy prevents myocardial hypertrophy. In the brain, ACE is localized in multiple specific sites where its role is unknown. Following oral ACE-inhibitor treatment, effects are restricted predominantly to areas devoid of blood-brain barrier. Early studies suggest ACE inhibitors enhance cognition. In the testis, ACE is located in the seminiferous tubules where its function is unknown. It is not inhibited following oral ACE-inhibitor treatment. In the kidney and gastrointestinal tract, ACE is in high concentration in the epithelial brush border where its function is unknown. In clinical use ACE inhibitors primarily affect the cardiovascular system. With pharmacological developments, ACE inhibitors targeted for specific organs may have effects predominantly in the brain, heart, reproductive system, or gastrointestinal tract.en
dc.language.isoenen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.metabolism.pharmacology.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherBlood Vessels.enzymologyen
dc.subject.otherBrain.enzymologyen
dc.subject.otherHumansen
dc.subject.otherKidney.enzymologyen
dc.subject.otherMaleen
dc.subject.otherMyocardial Infarction.enzymologyen
dc.subject.otherMyocardium.enzymologyen
dc.subject.otherPeptidyl-Dipeptidase A.metabolismen
dc.subject.otherRatsen
dc.subject.otherRenin-Angiotensin System.physiologyen
dc.subject.otherTestis.enzymologyen
dc.titleAngiotensin-converting enzyme inhibition: prospects for the future.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Cardiovascular Pharmacologyen
dc.identifier.affiliationUniversity of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pagesS4-8en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/1725200en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.